CN Patent

CN119072311A — 用于膀胱内施用的厄达替尼制剂和渗透系统

Assigned to Liris Biomedical Inc · Expires 2024-12-03 · 1y expired

What this patent protects

本文提供了包含厄达替尼的L‑乳酸盐的固体药物组合物；用于制备此类制剂的方法；以及包含此类制剂的药物递送系统，包括用于膀胱内施用的系统。

USPTO Abstract

本文提供了包含厄达替尼的L‑乳酸盐的固体药物组合物；用于制备此类制剂的方法；以及包含此类制剂的药物递送系统，包括用于膀胱内施用的系统。

Drugs covered by this patent

Patent Metadata

Patent number
CN119072311A
Jurisdiction
CN
Classification
—
Expires
2024-12-03
Drug substance claim
No
Drug product claim
No
Assignee
Liris Biomedical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.